Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 18:8:F1000 Faculty Rev-194.
doi: 10.12688/f1000research.16627.1. eCollection 2019.

Non-immunological complications following kidney transplantation

Affiliations
Review

Non-immunological complications following kidney transplantation

Abraham Cohen-Bucay et al. F1000Res. .

Abstract

Kidney transplantation (KT) is the most effective way to decrease the high morbidity and mortality of patients with end-stage renal disease. However, KT does not completely reverse the damage done by years of decreased kidney function and dialysis. Furthermore, new offending agents (in particular, immunosuppression) added in the post-transplant period increase the risk of complications. Cardiovascular (CV) disease, the leading cause of death in KT recipients, warrants pre-transplant screening based on risk factors. Nevertheless, the screening methods currently used have many shortcomings and a perfect screening modality does not exist. Risk factor modification in the pre- and post-transplant periods is of paramount importance to decrease the rate of CV complications post-transplant, either by lifestyle modification (for example, diet, exercise, and smoking cessation) or by pharmacological means (for example, statins, anti-hyperglycemics, and so on). Post-transplantation diabetes mellitus (PTDM) is a major contributor to mortality in this patient population. Although tacrolimus is a major contributor to PTDM development, changes in immunosuppression are limited by the higher risk of rejection with other agents. Immunosuppression has also been implicated in higher risk of malignancy; therefore, proper cancer screening is needed. Cancer immunotherapy is drastically changing the way certain types of cancer are treated in the general population; however, its use post-transplant is limited by the risk of allograft rejection. As expected, higher risk of infections is also encountered in transplant recipients. When caring for KT recipients, special attention is needed in screening methods, preventive measures, and treatment of infection with BK virus and cytomegalovirus. Hepatitis C virus infection is common in transplant candidates and in the deceased donor pool; however, newly developed direct-acting antivirals have been proven safe and effective in the pre- and post-transplant periods. The most important and recent developments on complications following KT are reviewed in this article.

Keywords: kidney transplant; post-transplant complications.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AC-B declares that he has no competing interests. CEG served on a medical advisory board of Abbvie pharmaceuticals, as a consultant to Alexion Pharmaceuticals and on the evidence review team for the 2018 KDIGO guidelines on HCV. JMF served as a consultant to Alexion Pharmaceuticals.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. United Stated Renal Data System: 2017 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.2017. Reference Source
    1. Nakano T, Ninomiya T, Sumiyoshi S, et al. : Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis. 2010;55(1):21–30. 10.1053/j.ajkd.2009.06.034 - DOI - PubMed
    1. Chonchol M, Whittle J, Desbien A, et al. : Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol. 2008;28(2):354–60. 10.1159/000111829 - DOI - PubMed
    1. Ramphul R, Fernandez M, Firoozi S, et al. : Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol. BMC Nephrol. 2018;19(1):2. 10.1186/s12882-017-0795-z - DOI - PMC - PubMed
    1. Lentine KL, Costa SP, Weir MR, et al. : Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434–80. 10.1016/j.jacc.2012.05.008 - DOI - PubMed